<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor pathway limits <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> by inducing cell cycle arrest or <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>A key p53 target gene is PUMA, which encodes a <z:chebi fb="0" ids="30153">BH3</z:chebi>-only proapoptotic protein </plain></SENT>
<SENT sid="2" pm="."><plain>Here we demonstrate that Puma deletion in the Emu-Myc mouse model of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> accelerates <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> and that approximately 75% of Emu-Myc <z:hpo ids='HP_0002665'>lymphomas</z:hpo> naturally select against Puma protein expression </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, approximately 40% of primary human Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> fail to express detectable levels of PUMA and in some <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> this is associated with DNA methylation </plain></SENT>
<SENT sid="4" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines phenocopy the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> with respect to DNA methylation and diminished PUMA expression, which can be reactivated following inhibition of DNA methyltransferases </plain></SENT>
<SENT sid="5" pm="."><plain>These findings establish that PUMA is silenced in human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, and they suggest PUMA as a target for the development of novel chemotherapeutics </plain></SENT>
</text></document>